We are excited to announce a partnership with CTMC, a joint @IncResilience & @MDAndersonNews venture, to accelerate novel cell therapy delivery. 🙌 We are looking forward to working together to enable widespread patient access to cell therapies. ➡️

🔬 Researchers at @idibaps & @hospitalclinic have developed a next-gen CAR-T for resistance in non-Hodgkin lymphoma. Scaling breakthroughs to commercial availability requires rethinking CGT manufacturing so therapies are commercially viable & accessible.

Commercially approved cell therapies have treated >30,000 patients, but many still don't have access. In @Ori_JCFoster's interview at @jpmorgan, he shared how the complexity of CAR-T demands an approach that embraces automation & scalability ⬇️

Deshawn, 19, is among the first US patients to receive a CRISPR for sickle cell disease via @cityofhope in Dec '24. After years of excruciating pain, DJ is recovering well & is excited to try snowboarding which would have been impossible before.

🎙️@Ori_JCFoster recently joined @jonchee_excedr on The Biotech Startups Podcast. In this 2-part series, Jason shares his journey from early entrepreneurship to leading our mission of enabling widespread patient access to CGTs. 1️⃣ 2️⃣

🔬 A clinical trial from researchers at Stanford Medicine has that shown how CAR-T cell therapy can be used for treating pediatric brain tumors. Of 11 participants, 9 experienced neurological improvements & 7 experienced tumor shrinkage. Read more:

🔬 On the Ori Spotlight podcast, @Ori_JCFoster & Amritha Jaishankar, @IQVIA_global discussed how true patient accessibility encompasses infrastructure readiness, stakeholder collaboration, and comprehensive patient education. 🎧 Listen now:

At this year's @jpmorgan Annual Healthcare Conference, our CEO @Ori_JCFoster sat down with @endpts founder Arsalan Arif to discuss a fundamental question: can we get CGT to market in a way that makes sense clinically & commercially? Full discussion:

In 2020, high school junior Drew faced a diagnosis of a rare & often fatal brain cancer. Hope emerged through a @StanfordMed CAR-T therapy trial & by 2022, his tumour had disappeared allowing him to attend his graduation. Thanks @StanfordMed for sharing:

At this year’s #JPM25, Ori CEO @Ori_JCFoster joined @endpts' @AKAarsalan to discuss how automation and digitization are transforming CGT #manufacturing. Jason highlighted three key challenges to scalability: throughput, COGs & quality. Watch:

🔬The ‘memory’ within CAR-T cells reveals how prior antigen encounters influence their behaviour. By targeting RUNX2 genes, scientists at @CUSystem are exploring ways to enhance the efficacy of naïve T cells while reducing cell exhaustion. Read more ➡️

On the Ori Spotlight Podcast, Michael Krajewski, joined @Ori_JCFoster to share his journey of transforming the steel industry through automation, a mission that mirrors the challenges in CGT #Manufacturing. 🎧Listen now:

🔬Researchers have developed CAR-T cells targeting p95HER2, a tumour-specific protein found exclusively in HER2-amplified solid tumours. While this method is still in its early stages; the findings suggest new treatment pathways for ~4% of all tumors⬇️

For Missy, mother of 2, the return of her melanoma brought challenges – but also a chance to explore TIL therapy at @ClevelandClinic. Today, her cancer continues to shrink. “I may not be here right now if it wasn’t for this new treatment...” says Missy.

Delivering on our promise to scale the impact of CGTs. With the first IRO® platforms now in use by leading CDMOs & a global pharmaceutical company, we’ve taken a significant step towards achieving our mission of enabling widespread #PatientAccess⬇️

At last week's @AllianceRM State of the Industry Briefing at @jpmorgan, we joined leaders across the CGT sector to hear how the field's progress & trajectory is shaping up for 2025. Our key takeaways ⬇️ Watch the full discussion:

On the Ori Spotlight Podcast, Boro Dropulić, CEO of Vector BioMed & Executive Director of Caring Cross, joined @Ori_JCFoster to explore how hospital-based #Manufacturing can cut development costs & enable #PatientAccess. 🎧Listen:

✈️ Kale Feeter and Sarah Haecker from the Ori team have touched down at @Phacilitate #AdvancedTherapies Week in Dallas. If you’re attending and would like to learn how we're scaling the impact of advanced therapies, get in touch. Read more:

Darlene is preparing to receive CAR-T therapy for multiple myeloma, which her oncologist anticipates could provide years of remission. Her journey highlights the need to ensure these therapies are not only approvable but accessible and affordable too. ➡️

Disclaimer: These numbers are inferred from publicly reported revenue numbers & therefore, are directionally correct but likely specifically wrong. They wouldn't account for patients previously treated in clinical trials or those treated on compassionate use who were not charged.